September 30, 2024 at 3:38 pm

Natural Alternatives (NAII) Trades Down Over 12% on Q4 Earnings Report

The supplement and health centric company Natural Alternatives (NAII) is lagging the PRISM Consumer Products Index today upon the announcement of its Q4 earnings that was released after the close on Friday. The company reported a net loss of $1.9M million, or ($0.32) per diluted share, on net sales of $29.5M for Q4 compared to… [Read More]
September 30, 2024 at 11:39 am

Klotho Neurosciences (KLTO) Bolsters Advisory Board with Biotech Powerhouse Dr. Robert Langer, Co-Founder of Moderna

Biotech Pioneer to Drive Klotho’s Pipeline in Neuroscience and Therapeutic Development Strategic Expansion Targeting Multi-Billion-Dollar Markets with Patented Klotho Gene Technology Klotho Neurosciences, Inc. (Nasdaq: KLTO), a leader in developing therapies for neurodegenerative diseases and promoting healthy longevity, announced a pivotal milestone: Dr. Robert Langer, co-founder of Moderna, has joined its Scientific Advisory Board. Dr…. [Read More]
September 30, 2024 at 11:18 am

BioStem Technologies (BSEM) Takes Major Leap Towards Nasdaq Uplisting Amidst Record Revenue Growth, Targeting Enhanced Market Visibility and Global Liquidity

BioStem Technologies (OTC: BSEM) has filed a Form 10 registration with the SEC, marking a critical step toward its planned uplisting to Nasdaq. The Company aims to be a fully reporting entity within 60 days, complying with quarterly and annual reporting requirements. Jason Matuszewski, CEO of BioStem Technologies, commented: “Our decision to pursue a major… [Read More]
September 30, 2024 at 11:10 am

BrainsWay Secures $20 Million Private Placement with Valor Equity Partners; Shares Rise 12%

BrainsWay (NASDAQ: BWAY) has entered into a private investment financing deal with Valor Equity Partners, a firm renowned for supporting industry leaders such as SpaceX, Tesla, Neuralink, and Harmony Biosciences. This investment brings in gross proceeds of approximately $20 million and will drive BrainsWay’s strategic initiatives, including market expansion, data analysis enhancements, R&D development, and… [Read More]
September 30, 2024 at 8:45 am

Stocks making the biggest moves premarket: Nio, Stellantis, MicroStrategy and more

Before the opening bell, here’s a snapshot of some notable companies making headlines: Nio’s US-listed shares experienced a surge of over 13% as the Chinese electric vehicle manufacturer disclosed a financial boost of 13.3 billion yuan for its China-based entity, Nio China. The funds, a blend of capital from “strategic investors” and Nio Inc., will… [Read More]
September 27, 2024 at 2:06 pm

Establishment Labs (ESTA) Wins FDA Approval for Motiva Implants

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to women’s health and wellness, has received U.S. FDA approval for its Motiva® SmoothSilk® Ergonomix® and Motiva® SmoothSilk® Round breast implants. The company is currently leading the PRISM Women’s Health Index, with shares trading up 13%.   Highlights: Advanced Breast Implants: Motiva® SmoothSilk®… [Read More]
September 27, 2024 at 12:18 pm

Biotech’s Vital Signs: A Pulse on Recovery and Growth Opportunities

Sector Starting to Show Signs of Life The biotech sector, particularly small-cap biotech, is showing a positive outlook as multiple macroeconomic factors align to create a conducive environment for growth. After facing the headwinds of rising interest rates and economic uncertainty for several years, the sector is beginning to recover, signaling potential opportunities for investors… [Read More]
September 27, 2024 at 8:27 am

Stocks making the biggest moves premarket: Bristol-Myers Squibb, Costco, Super Micro Computer and more

Dive into the latest premarket trading highlights. Bristol-Myers Squibb’s biopharmaceutical stocks have leaped by 5.3% following the FDA approval of Cobenfy for schizophrenia treatment in adults, marking a breakthrough after decades without a new treatment type. Novo Nordisk, a Danish healthcare firm, saw a 2.9% slide in its U.S.-listed shares after JPMorgan predicted a Q3… [Read More]
September 26, 2024 at 5:54 pm

Sage Therapeutics and Biogen End Collaboration on SAGE-324 Program

Sage Therapeutics, Inc. (NASDAQ: SAGE) announced the discontinuation of its collaboration with Biogen Inc. (NASDAQ: BIIB) on the SAGE-324 program following recent negative Phase 2 trial results. Despite this, the companies will continue their partnership on ZURZUVAE®, the first FDA-approved oral treatment for postpartum depression (PPD). Key Highlights: Discontinuation of SAGE-324 Program: Biogen has terminated… [Read More]
September 26, 2024 at 12:10 pm

What Are the Bad Boys Going to Do? Veritone (VERI) Teams Up with Midwest Public Safety on AI-Powered Law Enforcement Platforms

The PRISM AdTech and Media Index company Veritone, Inc. (VERI), who is a leading provider of human-centered enterprise AI solutions, has announced a new partnership with Midwest Public Safety, a top supplier of public safety technology solutions. Upon their agreement, Midwest Public Safety will offer its current and potential customers Veritone Public Sector’s full suite… [Read More]